News

4D Molecular Therapeutics, Inc.: 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...
TMCnet16h

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...
Medscape19h

New Anti-VEGF Agents Extend Dosing Intervals in Wet AMD

New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...